Triple Blood Marker Combination Predicts Heart Disease Risk in Women

A three-decade study of nearly 28,000 American women has identified a combination of blood markers that can forecast heart disease risk with striking precision—sometimes decades before symptoms appear. The research, funded by the National Institutes of Health and presented at the European Society of Cardiology Congress in 2024, found that when three specific measurements climb together in the bloodstream, a woman's chances of suffering a heart attack or stroke multiply dramatically.

The Women's Health Study enrolled 27,939 healthcare providers between 1992 and 1995, when most were around 55 years old. Researchers collected blood samples and tracked these women for 30 years. During that span, 3,662 of them experienced a major cardiovascular event—a heart attack, stroke, surgery to restore blood flow to the heart, or death from heart disease. This wasn't a small or theoretical group; it was a substantial portion of the cohort, and their medical histories provided the raw material for understanding which blood markers predicted trouble.

The three markers examined were familiar to cardiologists but had never been studied together in this way. Low-density lipoprotein cholesterol, or LDL, is the "bad" cholesterol that accumulates in artery walls. Lipoprotein(a), known as Lp(a), is a related lipid particle that carries LDL and appears to be partly inherited. C-reactive protein, or CRP, is a sign of inflammation coursing through the body. Individually, each one mattered. Women with the highest LDL levels faced a 36 percent increased risk compared to those with the lowest. Those with the highest Lp(a) faced a 33 percent increase. But CRP told the starkest story: women with the highest inflammation markers had a 70 percent increased risk.

What made the findings remarkable was what happened when all three climbed together. Women with elevated levels across all three markers faced more than three times the risk of coronary heart disease and one and a half times the risk of stroke compared to women with the lowest levels. The interaction between inflammation and lipids appeared to compound the danger—immune cells sensing cholesterol buildup or arterial plaque activation would trigger inflammatory signals, creating what researchers described as a hyperinflammatory environment where plaque could form, expand, or rupture and trigger a cardiovascular event.

Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital and a lead author, framed the stakes plainly: "We can't treat what we don't measure, and we hope these findings move the field closer to identifying even earlier ways to detect and prevent heart disease." The implication was clear—if doctors could identify women with this dangerous combination of markers, intervention might prevent catastrophe.

Yet the path from discovery to clinical practice remains uneven. LDL cholesterol is routinely measured and easily treated with statins, medications available for decades. Lp(a) screening, however, varies by country; some nations recommend universal testing because elevated levels often run in families, while in the United States it is typically ordered only for people with existing heart disease or a family history of it. CRP testing is even more discretionary, left largely to individual physician judgment. A new anti-inflammatory drug called colchicine, repurposed from gout treatment, was approved by the FDA in 2023 for people with atherosclerosis, and researchers are developing additional therapies. But widespread screening and treatment protocols do not yet exist.

The researchers emphasized that the findings applied to prevention at every stage of life. Regular physical activity, a heart-healthy diet, stress management, and avoiding tobacco all matter. For those identified as high-risk, medication to lower cholesterol or reduce inflammation might be warranted. The study suggested that choices made years or decades earlier accumulate, shaping cardiovascular health outcomes far into the future. The question now is whether the medical system will adapt quickly enough to measure these markers widely and act on what they reveal.